Substituted Methanimine Derivatives: Neurodegenerative Disease Assessment of (E)-1-Phenyl-N-(2-Phenyl)-1,3-Benzoxazol-6-YL) Methanimine Derivates for Parkinson's Disease.. DE
-
- Englisch ausgewählt
Fr. 61.90
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
23.01.2026
Verlag
OmniScriptumSeitenzahl
52
Maße (L/B/H)
22/15/0.4 cm
Gewicht
96 g
Sprache
Englisch
ISBN
978-620-9-57570-9
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the striatum and the presence of Lewy bodies composed mainly of ¿-synuclein. Sirtuin 2 (SIRT2), a class III histone deacetylase, is known to influence key cellular functions such as genome integrity, mitochondrial regulation, autophagy, and apoptosis. Increased SIRT2 expression in aging and PD models highlights its relevance as a potential therapeutic target. In this study, a set of Benzoxazole-based methanimine derivatives, (E)-1-Phenyl-N-(2-Phenyl)-1,3-benzoxazol-6-yl) methanimine analogues (NOV 1-3), were designed and evaluated for their inhibitory potential against SIRT2. The target protein (PDB ID: 5YQL) was obtained from the RCSB PDB database, refined through loop modelling, and energy-minimized before molecular docking analysis. Docking studies showed that NOV 1-3 exhibited strong binding affinities and key interactions within the SIRT2 active site, suggesting effective inhibition. The synthesized compounds were structurally confirmed using IR, NMR, and mass spectroscopy.
Kundinnen und Kunden meinen
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kund*innen durch Ihre Meinung